Trial Profile
Persistence of Bactericidal Antibodies in Adults Who Received a Booster Dose of Menactra Approximately Four Years Earlier
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 15 Feb 2019
Price :
$35
*
At a glance
- Drugs Meningococcal vaccine groups A B C Y W-135 conjugate (Primary)
- Indications Meningococcal infections
- Focus Pharmacodynamics
- Sponsors Sanofi Pasteur
- 19 Jan 2019 Results assessing the persistence of bactericidal antibodies 4 years afer a MenACWY booster dose published in the Vaccine
- 01 Mar 2016 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 07 Jan 2016 According to ClinicalTrials.gov record, status changed from recruiting to active, no longer recruiting.